HUMA

Humacyte Inc

Sep 17 • 04:00PM ET

1.53

-0.04 -2.55 %

Healthcare • Biotechnology • USA • NASD

Peers: MDXG NVRO CRBP ATEC AXGN ARCT RGEN XGN MIRM ZLAB

| Held by: VTI IWM XBI VXF IWN IBB VTWO SCHA VHT IWC

Index	RUT	P/E	-	EPS (ttm)	-0.46	Insider Own	17.20%	Shs Outstand	156.34M	Perf Week	3.38%
Market Cap	243.02M	Forward P/E	-	EPS next Y	-0.35	Insider Trans	-13.81%	Shs Float	131.52M	Perf Month	-15.00%
Enterprise Value	288.65M	PEG	-	EPS next Q	-0.15	Inst Own	36.77%	Short Float	25.55%	Perf Quarter	-34.33%
Income	-61.03M	P/S	296.37	EPS this Y	70.20%	Inst Trans	-5.82%	Short Ratio	7.96	Perf Half Y	-51.12%
Sales	0.82M	P/B	59.03	EPS next Y	6.56%	ROA	-44.06%	Short Interest	33.60M	Perf YTD	-69.70%
Book/sh	0.03	P/C	6.39	EPS next 5Y	-	ROE	-257.38%	52W High	6.77 -77.40%	Perf Year	-72.87%
Cash/sh	0.24	P/FCF	-	EPS past 3/5Y	-23.74% 42.43%	ROIC	-73.98%	52W Low	1.15 33.04%	Perf 3Y	-65.85%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-837.90%	Volatility	5.78% 7.14%	Perf 5Y	-
Dividend TTM	-	EV/Sales	352.01	EPS Y/Y TTM	63.92%	Oper. Margin	-13598.04%	ATR (14)	0.13	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.93	Sales Y/Y TTM	-100.00%	Profit Margin	-7461.49%	RSI (14)	42.17	Recom	1.43
Dividend Gr. 3/5Y	- -	Current Ratio	2.45	EPS Q/Q	49.04%	SMA20	1.22%	Beta	1.87	Target Price	8.43
Payout	-	Debt/Eq	20.66	Sales Q/Q	-	SMA50	-22.07%	Rel Volume	0.45	Prev Close	1.57
Employees	220	LT Debt/Eq	19.37	Earnings	Aug 11 BMO	SMA200	-44.99%	Avg Volume	4.22M	Price	1.53
IPO	Dec 01, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-48.33% -70.00%	Trades		Volume	1,892,324	Change	-2.55%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-27-25	Initiated	Barclays	Overweight	$3.50
May-14-25	Resumed	H.C. Wainwright	Buy	$4
Dec-20-24	Reiterated	H.C. Wainwright	Buy	$12 → $15
Dec-11-23	Initiated	H.C. Wainwright	Buy	$6
Aug-14-23	Upgrade	Piper Sandler	Underweight → Neutral	$2.75 → $3.50
Jun-22-23	Initiated	Cantor Fitzgerald	Overweight	$6
May-16-22	Downgrade	Piper Sandler	Overweight → Underweight	$10 → $4
Oct-29-21	Initiated	Cowen	Outperform	$17
Sep-24-21	Initiated	Oppenheimer	Outperform	$16
Sep-22-21	Initiated	BTIG Research	Buy	$19
Sep-16-21	Initiated	Piper Sandler	Overweight	$17

Show Previous Ratings

Today 07:00AM	Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG) (GlobeNewswire)
Sep-15-25 07:00AM	Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess (GlobeNewswire)
Aug-20-25 09:30AM	Is It Worth Investing in Humacyte, Inc. (HUMA) Based on Wall Street's Bullish Views? (Zacks)
Aug-12-25 03:03AM	Humacyte Inc (HUMA) Q2 2025 Earnings Call Highlights: Navigating Challenges and Celebrating ... (GuruFocus.com)
Aug-11-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -29.64%
08:15AM	Loading…
08:15AM	Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-07-25 08:00AM	Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025 (GlobeNewswire) +11.76%
Aug-06-25 06:00PM	Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts (Zacks)
Jul-31-25 06:00PM	Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights (Zacks) -5.00%
Jul-25-25 06:00PM	Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts (Zacks) -5.24%
Jul-24-25 06:15PM	Humacyte, Inc. (HUMA) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
Jul-23-25 08:00AM	Humacyte Announces First Symvess Sale to Military Treatment Facility (GlobeNewswire) +18.70%
Jul-18-25 06:00PM	Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know (Zacks)
Jul-15-25 06:15PM	Why Humacyte, Inc. (HUMA) Dipped More Than Broader Market Today (Zacks) -7.69%
06:15PM	Loading…
Jul-09-25 06:15PM	Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors (Zacks)
Jul-08-25 08:00AM	Humacyte announces Symvess ECAT Approval from U.S. Defense Logistics Agency (GlobeNewswire) +18.98%
Jul-07-25 09:08AM	Beat the Market the Zacks Way: Humacyte, Starbucks, Oracle in Focus (Zacks) -5.26%
Jun-30-25 06:00PM	Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors (Zacks) +9.09%
Jun-25-25 06:15PM	Humacyte, Inc. (HUMA) Stock Moves -1.79%: What You Should Know (Zacks)
Jun-18-25 06:00PM	Humacyte, Inc. (HUMA) Gains As Market Dips: What You Should Know (Zacks)
Jun-09-25 08:00AM	Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting (GlobeNewswire)
Jun-02-25 08:00AM	Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3 (GlobeNewswire)
May-30-25 09:30AM	Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
May-19-25 04:05PM	Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq (GlobeNewswire) +11.66%
May-13-25 08:45AM	Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +31.06%
07:30AM	Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-09-25 08:00AM	Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025 (GlobeNewswire)
Apr-30-25 06:00PM	Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
12:00PM	All You Need to Know About Humacyte, Inc. (HUMA) Rating Upgrade to Buy (Zacks)
06:00PM	Loading…
Apr-24-25 06:00PM	Humacyte, Inc. (HUMA) Ascends But Remains Behind Market: Some Facts to Note (Zacks)
Apr-16-25 06:15PM	Humacyte, Inc. (HUMA) Increases Despite Market Slip: Here's What You Need to Know (Zacks) +8.39%
Apr-03-25 06:00PM	Humacyte, Inc. (HUMA) Stock Moves -0.68%: What You Should Know (Zacks) -6.90%
Mar-29-25 12:05PM	Lululemon reports Q4 beat, CoreWeave IPO priced at $40: Morning Buzz (TipRanks)
10:40AM	Humacyte price target lowered to $8 from $10 at BTIG (TipRanks)
Mar-28-25 01:48PM	Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript (Seeking Alpha)
07:30AM	Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-26-25 04:28PM	Humacyte: Doubts Cast Around Efficacy Of Symvess May Be Hard To Dispel (SeekingAlpha) -30.43%
09:30AM	Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet (Zacks)
08:00AM	Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025 (GlobeNewswire)
Mar-25-25 08:35PM	Humacyte, Inc. Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -13.40%
04:01PM	Humacyte, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Mar-24-25 06:00PM	Humacyte, Inc. (HUMA) Flat As Market Gains: What You Should Know (Zacks)
10:42AM	Humacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade) (SeekingAlpha)
Mar-10-25 08:00AM	Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics (GlobeNewswire) -6.15%
Mar-06-25 08:00AM	Trestle Bio Announces Research Collaboration with Humacyte (Business Wire) -6.03%
Mar-03-25 08:00AM	Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025 (GlobeNewswire) -10.15%
Feb-27-25 04:05PM	Humacyte to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
08:00AM	Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess and Other Bioengineered Tissues (GlobeNewswire)
Feb-26-25 08:00AM	Humacyte Announces Commercial Launch of Symvess (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma (GlobeNewswire) +12.83%
Jan-28-25 08:00AM	Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP ) Development Using iPSCs (GlobeNewswire)
Jan-21-25 08:00AM	Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV for Coronary Artery Bypass Grafting (GlobeNewswire)
Jan-17-25 05:14AM	Humacyte, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - HUMA (PR Newswire)
Jan-13-25 12:02PM	Humacyte, Inc. Sued for Securities Law Violations Investors Should Contact Levi and Korsinsky Before January 17, 2025 to Discuss Your Rights HUMA (GlobeNewswire)
08:00AM	Humacyte Provides Update on Commercial Launch and Pricing of Symvess (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma (GlobeNewswire)
Jan-03-25 05:30AM	Humacyte, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your Rights - HUMA (PR Newswire)
Jan-02-25 10:07AM	Humacyte, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - HUMA (PR Newswire)
Dec-24-24 08:25AM	Humacyte price target raised to $17 from $15 at Benchmark (TipRanks)
Dec-19-24 10:47PM	Humacyte Announces FDA Approval of SYMVESS (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma (GlobeNewswire) +34.10%
01:24PM	Humacyte's (HUMA) Insiders Sell Millions in Stock Amidst Lawsuit and Regulatory Troubles Hagens Berman (GlobeNewswire)
Dec-16-24 03:36PM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations Hagens Berman (GlobeNewswire) +5.85%
01:45PM	Investors in Humacyte, Inc. Should Contact Levi and Korsinsky Before January 17, 2025 to Discuss Your Rights HUMA (GlobeNewswire)
Dec-12-24 11:48AM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations Hagens Berman (GlobeNewswire)
Dec-11-24 01:00PM	Investors in Humacyte, Inc. Should Contact Levi and Korsinsky Before January 17, 2025 to Discuss Your Rights HUMA (GlobeNewswire)
12:20PM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations - Hagens Berman (Newsfile)
Dec-09-24 01:32PM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations Hagens Berman (GlobeNewswire) -12.73%
Dec-06-24 05:52AM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations - Hagens Berman (Newsfile) +7.57%
Dec-05-24 11:08AM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations Hagens Berman (GlobeNewswire)
Dec-02-24 03:05PM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations Hagens Berman (GlobeNewswire)
09:05AM	Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
05:45AM	Shareholders of Humacyte, Inc. Should Contact Levi and Korsinsky Before January 17, 2025 to Discuss Your Rights - HUMA (PR Newswire)
Nov-28-24 10:41AM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations Hagens Berman (GlobeNewswire)
Nov-22-24 08:30AM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations - Hagens Berman (Newsfile)
08:00AM	Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH) (GlobeNewswire)
Nov-21-24 08:00AM	Humacyte Clinical Results Highlighting Benefit of the ATEV in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery (GlobeNewswire)
Nov-18-24 08:00AM	Humacyte Presents Preclinical Results of Small-Diameter ATEV for Coronary Artery Bypass Grafting at American Heart Association's Scientific Sessions 2024 (GlobeNewswire) -8.07%
Nov-15-24 01:32PM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations Hagens Berman (GlobeNewswire)
Nov-14-24 08:00AM	Humacyte Announces Pricing of $15.0 Million Registered Direct Offering (GlobeNewswire) -9.36%
Nov-11-24 04:37PM	Humacyte (HUMA) Faces Questions After FDA Inspection Hagens Berman (GlobeNewswire)
Nov-08-24 09:16AM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations Hagens Berman (GlobeNewswire) +9.89%
08:00AM	Humacyte Third Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Nov-06-24 08:00AM	Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 8, 2024 (GlobeNewswire)
Nov-04-24 06:34PM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations Hagens Berman (GlobeNewswire) -5.94%
Oct-31-24 02:16PM	Humacyte (HUMA) Faces Questions After FDA Inspection Hagens Berman (GlobeNewswire)
Oct-28-24 06:08PM	Humacyte's (HUMA) Statements to Investors Called Into Question in Light of FDA Violations Hagens Berman (GlobeNewswire)
07:00AM	Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology's Kidney Week 2024 (GlobeNewswire)
Oct-24-24 02:55PM	Humacyte (HUMA) Faces Questions After FDA Inspection Hagens Berman (GlobeNewswire)
Oct-23-24 08:00AM	Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV ) for AV Access in Hemodialysis on October 31, 2024 (GlobeNewswire)
Oct-16-24 08:00AM	Its Spare Parts for People: Blood Vessels Grown in a Lab (The Wall Street Journal)
Oct-08-24 08:00AM	Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology's Kidney Week 2024 (GlobeNewswire)
06:30AM	Humacyte Launches $30M Stock and Warrants Offering (TipRanks)
Oct-04-24 08:00AM	Humacyte Announces Pricing of $30.0 Million Registered Direct Offering (GlobeNewswire)
Sep-26-24 05:26PM	Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV ) in Vascular Trauma Treatment on September 30, 2024 (GlobeNewswire)
Sep-19-24 08:00AM	Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP ) (GlobeNewswire)
Sep-03-24 08:00AM	Humacyte to Participate at Upcoming Investor Conferences in September (GlobeNewswire) -8.51%
Aug-27-24 08:00AM	Humacyte Presents Positive Long-Term Results of ATEV in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program (GlobeNewswire) -5.53%
Aug-13-24 07:00AM	Humacyte Second Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Aug-12-24 08:00AM	Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 13, 2024 (GlobeNewswire) -16.37%
07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Aug-09-24 04:05PM	Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV) BLA for the Treatment of Vascular Trauma (GlobeNewswire)

Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dougan Brady W	Director	Aug 19 '25	Sale	1.63	1,100,000	1,793,000	591,685	Aug 20 07:30 PM
Dougan Brady W	Director	Aug 18 '25	Sale	1.83	549,360	1,005,329	1,691,685	Aug 20 07:30 PM
Dougan Brady W	Director	Aug 20 '25	Sale	1.58	591,685	934,862	0	Aug 20 07:30 PM
Niklason Laura E	President, CEO and Director	Aug 19 '25	Sale	1.63	1,100,000	1,793,000	591,685	Aug 20 07:29 PM
Niklason Laura E	President, CEO and Director	Aug 18 '25	Sale	1.83	549,360	1,005,329	1,691,685	Aug 20 07:29 PM
Niklason Laura E	President, CEO and Director	Aug 20 '25	Sale	1.58	591,685	934,862	0	Aug 20 07:29 PM
AYABUDGE LLC	Director	Aug 20 '25	Proposed Sale	1.58	591,685	936,654		Aug 20 04:17 PM
AYABUDGE LLC	Director	Aug 19 '25	Proposed Sale	1.63	1,100,000	1,790,244		Aug 19 04:20 PM
AYABUDGE LLC	Director	Aug 18 '25	Proposed Sale	1.83	549,360	1,002,928		Aug 18 04:28 PM
Scheessele William John	Chief Commercial Officer	Apr 14 '25	Buy	1.54	6,493	9,999	22,018	Apr 15 04:03 PM
Sander Dale A.	CFO and Chief Corp. Deve. Off.	Apr 10 '25	Buy	1.53	20,000	30,600	40,600	Apr 14 09:00 AM
Parikh Shamik J	Chief Medical Officer	Apr 10 '25	Buy	1.55	7,500	11,625	7,500	Apr 14 09:00 AM
Sebelius Kathleen	Director	Apr 08 '25	Buy	1.32	50,000	66,000	91,207	Apr 08 04:15 PM
Green Charles Bruce	Director	Apr 08 '25	Buy	1.29	6,000	7,740	8,400	Apr 08 04:15 PM
Constantino Michael T.	Director	Apr 07 '25	Buy	1.26	16,000	20,160	32,950	Apr 08 04:15 PM
Constantino Michael T.	Director	Dec 04 '24	Buy	4.39	4,600	20,181	16,950	Dec 04 04:05 PM
Niklason Laura E	President, CEO and Director	Nov 19 '24	Buy	4.44	1,797	7,979	243,851	Nov 21 07:31 AM
Dougan Brady W	Director	Nov 19 '24	Buy	4.44	1,797	7,979	243,851	Nov 21 07:30 AM
Niklason Laura E	President, CEO and Director	Nov 18 '24	Sale	4.44	811,172	3,601,604	2,419,712	Nov 20 07:06 PM
Niklason Laura E	President, CEO and Director	Nov 19 '24	Sale	4.34	427,459	1,855,172	1,992,253	Nov 20 07:06 PM
Niklason Laura E	President, CEO and Director	Nov 20 '24	Sale	4.40	261,369	1,150,024	1,730,884	Nov 20 07:06 PM
Dougan Brady W	Director	Nov 18 '24	Sale	4.44	811,172	3,601,604	2,419,712	Nov 20 07:02 PM
Dougan Brady W	Director	Nov 19 '24	Sale	4.34	427,459	1,855,172	1,992,253	Nov 20 07:02 PM
Dougan Brady W	Director	Nov 20 '24	Sale	4.40	261,369	1,150,024	1,730,884	Nov 20 07:02 PM
AYABUDGE LLC	Director	Nov 20 '24	Proposed Sale	4.40	261,369	1,149,218		Nov 20 04:12 PM
AYABUDGE LLC	Director	Nov 19 '24	Proposed Sale	4.34	427,459	1,854,067		Nov 19 04:17 PM
AYABUDGE LLC	Director	Nov 18 '24	Proposed Sale	4.44	811,172	3,603,981		Nov 18 04:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HUMA

Humacyte Inc

Upgrade your FINVIZ experience